Prognostic O
impact O
of O
pathological O
complete O
remission O
after O
preoperative O
irradiation O
in O
patients O
with O
locally O
advanced O
head O
and O
neck O
squamous O
cell O
carcinoma O
: O
re O
- O
analysis O
of O
a O
phase B-STYPE
3 I-STYPE
clinical I-STYPE
study I-STYPE
Prognostic O
impact O
of O
pathological O
complete O
remission O
after O
preoperative O
irradiation O
in O
patients O
with O
locally O
advanced O
head O
and O
neck O
squamous O
cell O
carcinoma O
: O
re O
- O
analysis O
of O
a O
phase B-STYPE
3 I-STYPE
clinical I-STYPE
study I-STYPE
05 O
Mar O
, O
2014 O
05 O
Mar O
, O
2014 O
KaiWang B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
JunlinYi B-AUTH
yijunlin1969@163.com O

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
XiaodongHuang O

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
YuanQu B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
JingweiLuo B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
JianpingXiao B-AUTH
ShipingZhang B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
YuanTang B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
WeixinLiu B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
LiGao B-AUTH

Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O
China O
ZhengangXu B-AUTH

Prognostic O
impact O
of O
pathological O
complete O
remission O
after O
preoperative O
irradiation O
in O
patients O
with O
locally O
advanced O
head O
and O
neck O
squamous O
cell O
carcinoma O
: O
re O
- O
analysis O
of O
a O
phase B-STYPE
3 I-STYPE
clinical I-STYPE
study I-STYPE

Prognostic O
impact O
of O
pathological O
complete O
remission O
after O
preoperative O
irradiation O
in O
patients O
with O
locally O
advanced O
head O
and O
neck O
squamous O
cell O
carcinoma O
: O
re O
- O
analysis O
of O
a O
phase B-STYPE
3 I-STYPE
clinical I-STYPE
study I-STYPE
KaiWang B-AUTH

China O
Beijing O
China O
Department O
of O
Radiation O
Oncology O
, O
National O
Cancer O
Center O
/ O
Cancer O
Hospital O
, O
Chinese O
Academy O
of O
Medical O
Sciences O
and O
Peking O
Union O
Medical O
College O
Beijing O

China O
Beijing O
China O
Prognostic O
impact O
of O
pathological O
complete O
remission O
after O
preoperative O
irradiation O
in O
patients O
with O
locally O
advanced O
head O
and O
neck O
squamous O
cell O
carcinoma O
: O
re O
- O
analysis O
of O
a O
phase B-STYPE
3 I-STYPE
clinical I-STYPE
study I-STYPE
05 O
Mar O
, O
2014 O
05 O
Mar O
, O
2014 O
05 O
Mar O
, O
2014 O
10.1186 O
/ O
s13014 O
- O
019 O
- O
1428 O
- O
4 O

Although O
surgery O
followed O
by O
radiotherapy O
and/or O
concurrent O
chemoradio O
- O
therapy O
has O
been O
the O
major O
treatment O
choice O
recommended O
by O
the O
NCCN O
guideline O
for O
treating O
locally O
advanced O
head O
and O
neck O
squamous O
cell O
carcinoma O
( O
HNSCC O
) O
for O
many O
years O
[ O
1 O
] O
, O
the O
outcome O
with O
this O
regimen O
is O
still O
limited O
by O
a O
low O
5-year O
survival O
rate O
, O
which O
remains O
< O
40 O
% O
[ O
2,3 O
] O
. O
In O
recent O
years O
, O
several O
researches O
have O
suggested O
that O
preoperative O
radiotherapy O
and O
preoperative O
concurrent O
chemoradiotherapy O
may O
improve O
the O
overall O
survival O
( O
OS O
) O
compared O
to O
surgery O
alone O
in O
patients O
with O
head O
and O
neck O
cancer O
[ O
4][5][6 O
] O
. O
The O
advantages O
of O
preoperative O
radiotherapy O
or O
preoperative O
concurrent O
chemoradiotherapy O
for O
head O
and O
neck O
cancer O
include O
down O
- O
staging O
, O
increased O
resectability O
rate O
, O
etc O
. O
Further O
evidence O
from O
several O
phase O
2 O
studies O
have O
shown O
that O
preoperative O
concurrent O
chemoradiotherapy O
provides O
excellent O
treatment O
outcomes O
by O
leading O
to O
a O
pathological O
complete O
response O
rate O
ranging O
from O
35 O
to O
61 O
% O
and O
an O
increased O
5-year O
OS O
rate O
of O
up O
to O
70 O
- O
81.5 O
% O
[ O
5][6][7][8 O
] O
. O

Several O
authors O
have O
suggested O
that O
the O
pathological O
response O
to O
preoperative O
radiotherapy O
or O
chemoradiotherapy O
is O
a O
valuable O
prognostic O
factor O
for O
local O
control O
and O
OS O
[ O
9,10 O
] O
. O
In O
one O
of O
our O
randomized B-STYPE
phase I-STYPE
3 I-STYPE
studies I-STYPE
, O
we O
evaluated O
the O
role O
of O
adding O
concurrent B-DESC
cisplatin I-DESC
to I-DESC
v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - S T A R T - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v
preoperative  I-DESC | B-DESC
radiotherapy I-DESC
^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - S T O P - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^
in O
the O
treatment O
of O
locally O
advanced O
HNSCC O
[ O
11 O
] O
. O
In O
this O
study O
, O
222 O
eligible O
patients O
were O
randomly O
assigned O
to O
a O
preoperative B-DESC
radiotherapy I-DESC
group I-DESC
( O
n O
= O
118 O
) O
or O
a O
preoperative B-DESC
concurrent I-DESC
chemoradiotherapy I-DESC
group I-DESC
( O
n O
= O
104 O
) O
. O
The O
results O
revealed O
that O
preoperative B-DESC
concurrent I-DESC
chemoradiotherapy I-DESC
led O
to O
a O
significantly O
improved O
distant O
metastasis O
- O
free O
survival O
( O
DMFS O
) O
compared O
to O
preoperative B-DESC
radiotherapy I-DESC
alone I-DESC
. O
According O
to O
the O
protocol O
, O
non O
- O
responders O
( O
defined O
by O
< O
80 O
% O
reduction O
of O
the O
primary O
lesion O
after O
preoperative O
treatment O
) O
, O
subsequently O
underwent O
resection O
of O
the O
primary O
lesion O
with O
or O
without O
neck O
dissection O
depending O
on O
the O
nodal O
status O
. O
In O
total O
, O
72 O
non O
- O
responders O
( O
33.8 O
% O
) O
were O
observed O
in O
this O
phase B-STYPE
3 I-STYPE
study I-STYPE
. O

In O
the O
present O
study O
, O
we O
analyzed O
the O
relationships O
between O
pathological O
complete O
remission O
( O
pCR O
) O
and O
clinical O
outcomes O
in O
these O
72 O
non O
- O
responder O
patients O
. O

The O
details O
of O
the O
study O
design O
and O
data O
collection O
have O
been O
published O
in O
our O
previous O
study O
[ O
11 O
] O
. O
In O
brief O
, O
from O
September O
2002 O
to O
May O
2012 O
, O
a O
total O
of O
222 O
HNSCC O
patients O
were O
enrolled O
in O
this O
phase B-STYPE
3 I-STYPE
study I-STYPE
, O
among O
which O
104 O
patients O
were O
assigned O
to O
the O
preoperative B-DESC
concurrent I-DESC
chemoradiotherapy I-DESC
group I-DESC
and O
118 O
patients O
were O
assigned O
to O
the O
preoperative B-DESC
radiotherapy I-DESC
group I-DESC
. O

All O
these O
patients O
received O
radiotherapy B-DESC
with O
either O
twodimensional B-DESC
or O
intensity B-DESC
- I-DESC
modulated I-DESC
radiotherapy I-DESC
( O
IMRT B-DESC
) O
. O
Patients O
assigned O
to O
the O
chemoradiotherapy O
group O
additionally O
received O
concurrent O
chemotherapy O
with O
30 B-DOSAGE
mg/ I-DOSAGE
m I-DOSAGE
2 I-DOSAGE
cisplatin O
weekly B-DOSAGE
. O
The O
tumor O
response O
was O
assessed O
by O
computed O
tomography O
( O
CT O
) O
and/or O
magnetic O
resonance O
imaging O
( O
MRI O
) O
and O
endoscopy O
examination O
at O
the O
end O
of O
the O
5th O
week O
( O
50 O
Gy O
) O
. O
Non O
- O
responders O
( O
defined O
as O
< O
80 O
% O
reduction O
of O
the O
primary O
lesion O
volume O
) O
underwent O
resection O
of O
the O
primary O
tumor O
and O
modified O
neck O
dissection O
within O
4 O
- O
6 O
weeks O
after O
the O
completion O
of O
preoperative O
treatment O
. O
Seventy O
- O
two O
patients O
were O
non O
- O
responders O
, O
including O
35 O
patients O
in O
the O
preoperative B-DESC
radiotherapy I-DESC
group O
and O
37 O
patients O
in O
the O
chemoradiotherapy B-DESC
group I-DESC
. O

The O
surgical O
samples O
of O
all O
clinical O
non O
- O
responders O
were O
assessed O
pathologically O
, O
and O
patients O
were O
classified O
according O
to O
the O
pathological O
response O
as O
the O
pCR O
group O
and O
non O
- O
pCR O
group O
, O
depending O
on O
whether O
residual O
tumor O
cells O
remained O
in O
the O
surgical O
sample O
or O
not O
. O

After O
completion O
of O
the O
treatment O
plan O
, O
patients O
were O
followed O
up O
for O
a O
minimum O
of O
5 O
years O
or O
until O
death O
, O
with O
a O
regular O
frequency O
: O
at O
1 O
month O
, O
every O
3 O
months O
for O
the O
first O
2 O
years O
, O
every O
6 O
months O
for O
the O
2 O
- O
5 O
years O
after O
treatment O
, O
and O
every O
year O
thereafter O
. O

In O
our O
previous O
study O
, O
we O
revealed O
that O
in O
a O
subset O
of O
patients O
with O
primary O
tumors O
of O
the O
larynx O
- O
hypopharynx O
, O
preoperative B-DESC
chemoradiotherapy I-DESC
significantly O
improved O
the O
PFS B-METRIC
and O
DMFS O
, O
and O
also O
provided O
a O
borderline O
benefit O
in O
OS O
in O
compared O
with O
preoperative O
radiotherapy O
. O
Therefore O
, O
in O
the O
current O
study O
, O
a O
sub O
- O
analysis O
comparing O
clinical O
outcomes O
in O
patients O
with O
larynxhypopharynx O
primary O
tumors O
was O
performed O
. O

Log O
- O
rank O
test O
was O
applied O
to O
compare O
the O
differences O
in O
baseline O
characteristics O
between O
pCR O
and O
non O
- O
pCR O
patients O
. O
The O
LC O
, O
OS O
, O
PFS B-METRIC
and O
DMFS O
were O
calculated O
by O
the O
Kaplan O
- O
Meier O
method O
. O
The O
multivariate O
analysis O
were O
by O
Cox O
regressive O
analysis O
. O
All O
tests O
were O
two O
- O
sided O
and O
p O
< O
0.05 O
was O
considered O
statistically O
significant O
. O
All O
analyses O
were O
conducted O
using O
SPSS O
21.0 O
software O
( O
IBM O
Corporation O
, O
Armonk O
, O
New O
York O
, O
U.S O
) O
. O

The O
total O
of O
72 O
non B-DESC
- I-DESC
responders I-DESC
included O
37 O
patients O
in O
the O
preoperative B-DESC
concurrent I-DESC
chemoradiotherapy I-DESC
group I-DESC
( O
n O
= O
104 O
) O
and O
35 O
patients O
in O
the O
preoperative B-DESC
radiotherapy I-DESC
group I-DESC
( O
n O
= O
118 O
) O
. O
Among O
these O
72 O
non O
- O
responders O
, O
25 O
patients O
( O
34.7 O
% O
) O
achieved O
pCR O
, O
including O
10 O
patients O
( O
10/37 O
) O
in O
the O
chemoradiotherapy B-DESC
group I-DESC
and O
15 O
patients O
( O
15/25 O
) O
in O
the O
radiotherapy B-DESC
group I-DESC
( O
Table O
1 O
) O
. O
There O
were O
no O
significant O
differences O
between O
the O
pCR O
and O
non O
- O
pCR O
groups O
in O
terms O
of O
primary O
tumor O
site O
, O
tumor O
staging O
( O
T O
, O
N O
stage O
) O
, O
grades O
of O
clinical O
group O
, O
and O
treatment O
technique O
( O
all O
p O
> O
0.05 O
) O
. O

Over O
a O
median O
follow O
- O
up O
of O
24 O
months O
( O
range O
, O
3 O
- O
122 O
months O
) O
, O
the O
5-year O
estimated O
LC O
, O
OS O
, O
v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - S T A R T - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v
PFS B-METRIC
, O
and O
DMFS O
for O
pCR B-DESC
patients I-DESC
and O
non B-DESC
- I-DESC
pCR I-DESC
patients I-DESC
were O
93.2 O
% O
vs. O
67.7 O
% O
( O
p O
= O
0.007 O
) O
, O
83.3 O
% O
vs. O
39.7 O
% O
( O
p O
= O
0.0006 O
) O
, O
76.1 B-RESULTS
% I-RESULTS
vs. O
44.0 B-RESULTS
% I-RESULTS
(  B-RESULTS | I-RESULTS
p I-RESULTS
= I-RESULTS
0.003 I-RESULTS
) I-RESULTS
^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - S T O P - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^
, O
and O
90.4 O
% O
vs. O
56.3 O
% O
( O
p O
= O
0.005 O
) O
, O
respectively O
( O
Fig O
. O
1 O
) O
. O

There O
were O
46 O
v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - S T A R T - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v - v
non B-DESC
- I-DESC
responders  B-DESC | I-DESC
with O
larynxhypopharynx O
primary O
tumors O
, O
17 O
of O
whom O
achieved O
pCR O
of O
the O
primary O
lesion O
. O
The O
5-year O
estimated O
LC O
, O
OS O
, O
PFS B-METRIC
, O
and O
DMFS O
for O
these O
pCR B-DESC
and O
non B-DESC
- I-DESC
pCR I-DESC
patients O
were O
100 O
% O
vs. O
81.4 O
% O
( O
p O
= O
0.068 O
) O
, O
94.7 O
% O
vs. O
50.1 O
% O
( O
p O
= O
0.008 O
) O
, O
81.9 B-RESULTS
% I-RESULTS
vs. O
51.2 B-RESULTS
% I-RESULTS
(  B-RESULTS | I-RESULTS
p I-RESULTS
= I-RESULTS
0.03 I-RESULTS
) I-RESULTS
^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - S T O P - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^ - ^
, O
and O
94.1 O
% O
vs. O
61.1 O
% O
( O
p O
= O
0.02 O
) O
, O
respectively O
( O
Fig O
. O
2 O
) O
. O

In O
multivariate O
analysis O
, O
pCR O
was O
an O
independent O
prognostic O
factors O
of O
LC(p O
= O
0.002 O
) O
( O
Table O
2 O
) O
and O
OSwith O
statistically O
significant O
differences O
( O
p<0.001 O
) O
( O
Table O
3 O
) O
. O
And O
pCR O
also O
played O
an O
significant O
role O
in O
DMFS O
and O
PFS B-METRIC
( O
Additional O
file O
1 O
: O
Table O
S1 O
) O
. O
In O
addition O
, O
the O
degree O
of O
pathological O
differentiation O
, O
primary O
lesion O
in O
hypopharynx O
/ O
larynx O
and O
N O
stage O
were O
also O
independent O
prognostic O
factors O
for O
OS O
. O
Other O
factors O
such O
as O
gender O
, O
age O
, O
T O
stage O
, O
technology O
of O
radiation O
and O
chemotherapy O
were O
not O
independent O
prognostic O
factors O
for O
OS O
. O